CytRx Licenses RNAi Technology for ALS Research from U Mass Med School | GenomeWeb

CytRx Licenses RNAi Technology for ALS Research from U Mass Med School

Jun 30, 2003

NEW YORK, June 30 - CytRx today said it has signed an exclusive, worldwide, royalty-bearing license agreement with the University of Massachusetts Medical School (UMMS) to use UMMS's RNA interference technology in the development of a treatment for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Embryos Edited in US

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

True Blue

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

All the Plants

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

This Week in Nature

In Nature this week: a Danish reference genome, and more.